about
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivinFunction, regulation and pathological roles of the Gab/DOS docking proteinsLatent bone metastasis in breast cancer tied to Src-dependent survival signalsDynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalkMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerBreast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun PathwayProfiling Y561-dependent and -independent substrates of CSF-1R in epithelial cellsBCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signalingCurrent data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?Interaction of Src and Alpha-V Integrin Regulates Fibroblast Migration and Modulates Lung Fibrosis in A Preclinical Model of Lung FibrosisRole of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.Initiation factor eIF2-independent mode of c-Src mRNA translation occurs via an internal ribosome entry site.Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesPRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasionOpportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigmNovel dual Src/Abl inhibitors for hematologic and solid malignancies.Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancerReport from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancerControl of mammary tumor differentiation by SKI-606 (bosutinib).Abl kinases are required for invadopodia formation and chemokine-induced invasion.Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancerKnocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins.Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasionBosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyFulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cellsc-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis.Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.Signalling mechanisms regulating phenotypic changes in breast cancer cells.Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cellsSrc family kinases and paclitaxel sensitivity.Src regulates Tyr(20) phosphorylation of transferrin receptor-1 and potentiates breast cancer cell survivalSrc is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.Role of estrogen receptor signaling in breast cancer metastasis.
P2860
Q21195209-C9846C60-0DDD-4E38-9B83-EDF93B3FFE1FQ21245511-FDDA2B3A-4A40-40AD-813C-5B87F3C35BA4Q24648828-DFED6F86-640A-44FE-9F6B-C85361FB35D6Q26765201-307E9A10-EF35-4C96-B4D6-9FD40A97DC81Q26775086-051B3EA3-E18F-44F5-8D11-4F447245E5C9Q26825584-B3DD90D6-EDC3-4A74-ADF6-E762DE341264Q27316481-6635BDC8-A85C-4E85-99EA-916B183B209EQ28468471-F61B5A63-BCAC-4D8C-A62E-DFD0126B30D0Q28748716-A22EF908-CEA1-43F7-97B0-A52C8EC7E082Q30433442-FD2BB462-EB28-464B-9A11-2B2CF4A399DCQ33500786-0A03EC28-452B-49AB-A6E6-D135E13E444AQ33551808-F4D0152D-3133-4BE3-9441-EFA12412958BQ33641010-9A3C3405-8D7F-4B63-988C-C0507E64BAF9Q33648488-4CC7151B-434F-4DE3-BA31-F7448C281C1BQ33822560-2A30F60C-0355-47C9-A990-E9AF18D3B5CAQ33872677-C3CC3BFC-3031-4AED-BD0E-284F364C2D26Q33994282-67EE8F21-4BF4-47C8-ADB1-8BAC76BA79DEQ34121339-974F24BC-339C-4BC8-80D7-6F0332D23370Q34135475-C1BC5DBC-FCB0-4020-8D7E-458FE6840F44Q34211720-5B564607-4613-4B59-8DDD-A8C10D86E2F3Q34298754-3969AFD8-F47D-4953-A04B-61E2B0E834D6Q34387697-F7F378B5-0793-44BD-8B81-F3C46B6F2221Q34398204-1F706B3C-E9DD-4FA1-B399-6946C37E62ECQ34401096-A973709C-E2B3-4F79-A86B-65AC31434C15Q34408090-D6FB2754-6099-4E5C-96A6-1F2E5A031ACDQ34408095-EA4ABA9B-BCD5-447F-8351-D2837E56C096Q34473662-4B7DF8FB-14F1-43EF-BFF0-DB9515D0B72DQ34658293-3442287F-6CAE-4108-BAFB-958A74A2030AQ34674316-6DFE1413-69AF-4C07-B424-3B1544DC544AQ34756114-F2BE4A6A-CCFA-4BBD-9204-E469615457DCQ35034056-F685FBB4-2422-412C-8F6D-6550CE93C0AEQ35127916-D69C9A29-6DEE-4B70-8001-029EA00A5C10Q35207250-3E1CE1AC-BAB8-4E96-9CB8-EEEF0C58EF2FQ35207876-751ABF7F-97C3-4C7F-8299-3E8EBF594546Q35214722-0A150309-08F9-43C9-A4F8-5EBE0B7DA913Q35371875-543D4DA9-0D7C-45C5-82AA-3342FCC729E6Q35470139-4FB758F7-F081-4C49-AE35-700B4E525ABCQ35479665-30931636-7C3F-4E5F-96AE-E4ADF3402800Q35665700-5051F882-2362-4678-B6CC-4EB51CDAD1E6Q35684545-73C7D734-3070-4E2B-BAE4-14E2CED835DD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Src in breast cancer.
@en
Targeting Src in breast cancer.
@nl
type
label
Targeting Src in breast cancer.
@en
Targeting Src in breast cancer.
@nl
prefLabel
Targeting Src in breast cancer.
@en
Targeting Src in breast cancer.
@nl
P2860
P356
P1433
P1476
Targeting Src in breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDN291
P577
2008-05-16T00:00:00Z